High‐dose intranasal insulin in an adaptive dose‐escalation study in healthy human participants

Florian Schmitzberger, Jennifer Fowler, Cindy H. Hsu, Manjunath P. Pai, Robert W. Neumar, William J. Meurer, Robert Silbergleit · 2024

Read High‐dose intranasal insulin in an adaptive dose‐escalation study in healthy human participants by Florian Schmitzberger, Jennifer Fowler, Cindy H. Hsu, Manjunath P. Pai, Robert W. Neumar, William J. Meurer, Robert Silbergleit (2024) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-11573730.txt.

Description

Intranasal insulin is a putative neuroprotective therapy after cardiac arrest, but safety in humans at doses extrapolated from animal models is unknown. This phase I, open‐label adaptive dose‐escalation study explores the maximum tolerated dose of intranasal insulin in healthy human participants.

Catalog record

CREATORFlorian Schmitzberger, Jennifer Fowler, Cindy H. Hsu, Manjunath P. Pai, Robert W. Neumar, William J. Meurer, Robert Silbergleit
YEAR2024
COLLECTIONPAPERS
FORMATTXT
FILE SIZE29 KB
VERSION1.0
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC11573730

Browse the full library · About the Tower of Babel

Full text

The opening of the work, from the library's hosted text:

High‐dose intranasal insulin in an adaptive dose‐escalation study in healthy human participants Authors: Florian Schmitzberger, Jennifer Fowler, Cindy H. Hsu, Manjunath P. Pai, Robert W. Neumar, William J. Meurer, Robert Silbergleit Published: 2024 ABSTRACT AbstractIntranasal insulin is a putative neuroprotective therapy after cardiac arrest, but safety in humans at doses extrapolated from animal models is unknown. This phase I, open‐label adaptive dose‐escalation study explores the maximum tolerated dose of intranasal insulin in healthy human participants. Placebo or insulin at doses from 0 to 1000 units was given to healthy participants intranasally on repeated weekly visits. Serum glucose, insulin, and C‐peptide levels were measured serially at 0, 15, 30, 60, 120, 180, and 240 min after administration. Twenty‐four participants (12 female, median age 53, IQR 35–61) were enrolled. There was minimal change in average serum glucose after administration of intranasal insulin. Average serum insulin increased slightly in a dose‐dependent manner, reaching maximum concentrations at 15 min. C‐peptide decreased over time from administration in all groups. One participant had severe hypoglycemia (24 mg/dL at 45 min) and a different participant had mild hypoglycemia (51 mg/dL at 30 min), both after receiving 600 U intranasal insulin. Hypoglycemic episodes were associated with increases in serum insulin. Both participants continued in the study without hypoglycemia after additional doses. High‐dose intranasal insulin up to 1000 U was generally well tolerated, with minimal measurable systemic absorption and without significant aggregate changes in mean glucose. Idiosyncratic episodic systemic absorption and hypoglycemia require further study and additional caution in potential clinical application. Further study of its target engagement and efficacy as a neuroprotective therapy after cardiac arrest at these doses is warranted. Study Highlights WHAT IS THE CURRENT KNOWLEDGE ON THE TOPIC? Intranasal insulin has significant potential as a neuroprotective drug after cardiac arrest and other conditions. Intranasal application is fast and has been shown to be safe at lower doses. WHAT QUESTION DID THIS STUDY ADDRESS? This study demonstrated the safety and tolerability of intranasal insulin in healthy participants at doses up to 1000 U using an adaptive dose design. WHAT DOES THIS STUDY ADD TO OUR KNOWLEDGE? Dose‐dependent absorption of high doses of intranasal insulin and its effects on systemic glucose are clinically insignificant, but there appears to be rare idiosyncratic responses that are sometimes clinically important. HOW MIGHT THIS CHANGE CLINICAL PHARMACOLOGY OR TRANSLATIONAL SCIENCE? These results advance the evaluation of intranasal insulin as a potential neuroprotective agent that could be administered in the field post‐cardiac arrest and improve patient outcomes. High‐dose intranasal insulin appears mostly safe, allowing for the consideration of a trial to evaluate neuroprotection in humans during or immediately after cardiac arrest. Study Highlights WHAT IS THE CURRENT KNOWLEDGE ON THE TOPIC? WHAT IS THE CURRENT KNOWLEDGE ON THE TOPIC? WHAT IS THE CURRENT KNOWLEDGE ON THE TOPIC? Intranasal insulin has significant potential as a neuroprotective drug after cardiac arrest and other conditions. Intranasal application is fast and has been shown to be safe at lower doses. WHAT QUESTION DID THIS STUDY ADDRESS? WHAT QUESTION DID THIS STUDY ADDRESS? WHAT QUESTION DID THIS STUDY ADDRESS? This study demonstrated the safety and tolerability of intranasal insulin in healthy participants at doses up to 1000 U using an adaptive dose design. WHAT DOES THIS STUDY ADD TO OUR KNOWLEDGE? WHAT DOES THIS STUDY ADD TO OUR KNOWLEDGE? WHAT DOES THIS STUDY ADD TO OUR KNOWLEDGE? Dose‐dependent absorption of high doses of intranasal insulin and its effects on systemic glucose are clinically insignificant, but there appears to be rare idiosyncratic responses that are sometimes clinically important. HOW MIGHT THIS CHANGE CLINICAL PHARMACOLOGY OR TRANSLATIONAL SCIENCE? HOW MIGHT THIS CHANGE CLINICAL PHARMACOLOGY OR TRANSLATIONAL SCIENCE? HOW MIGHT THIS CHANGE CLINICAL PHARMACOLOGY OR TRANSLATIONAL SCIENCE? These results advance the evaluation of intranasal insulin as a potential neuroprotective agent that could be administered in the field post‐cardiac arrest and improve patient outcomes. High‐dose intranasal insulin appears mostly safe, allowing for the consideration of a trial to evaluate neuroprotection in humans during or immediately after cardiac arrest. INTRODUCTION Only 9% of the 146,924 victims of emergency medical services (EMS) treated out‐of‐hospital cardiac arrest (OHCA) in the US in 2021 in the Cardiac Arrest Registry to Enhance Survival (CARES) registry survived hospital discharge. 1 Among those initially successfully resuscitated, most die a neurological death from ischemic brain injury in the hospital. 2 Some pharmacologic therapies have shown neuroprotective properties in animal models; none have been successfully translated to clinical cardiac arrest care. 3 One reason for this failure to translate is that neuroprotective therapies are typically most effective if given very early after the onset of ischemia or reperfusion, which can be difficult to accomplish in the prehospital clinical setting. 4 Intranasal administration of insulin is a putative neuroprotective therapy for acute ischemic brain injury after cardiac arrest that could potentially be easily administered very rapidly during or immediately after resuscitation from cardiac arrest by lay or professional rescuers. 5 , 6 Insulin administered intranasally rapidly enters the central nervous system through an unusual direct‐nose‐to‐brain transport mechanism with minimal systemic circulatory absorption. 7 Intranasal administration of insulin has been tested in several human trials of other neurodegenerative disorders but not in patients with ischemic brain injury. 8 The neuroprotective effects of insulin are well established in animal models of acute brain ischemia, but preclinical experiments extrapolate to doses of intranasal insulin that exceed those already shown to be safe in previous human trials. 9 , 10 Therefore, we explored, in healthy participants, the safety of intranasal insulin within a range of doses potentially required to treat survivors of cardiac arrest, based on available preclinical data. Although there is a lack of good pharmacokinetic models to allow scaling of intranasal insulin dosing from animal models to humans, a substantial body of literature describes preclinical models of neurological injury demonstrating efficacy, but almost exclusively at much higher IN doses (typically 15 to 40 u/kg) than previously used in humans. We hypothesized that high‐dose intranasal insulin can be safely delivered to healthy human participants and sought to determine a maximum tolerated dose of intranasal insulin in humans. METHODS This study was approved by the University of Michigan institutional review board (HUM00171279). All protocols were approved by the US Food and Drug Administration under an investigational new drug application. All participants were informed of the purpose and nature of the study, and their written informed consent was obtained before any procedures were performed as part of this study. The consent form (S1) and study protocol (S2) are available as Supplemental Material. This was a phase I, open‐label dose‐finding study of intranasal insulin in healthy participants at a single site. The primary objective was to determine the safety of high‐dose nasal insulin or the maximum tolerated dose in healthy participants. Placebo or insulin at escalating doses from 0 to 1000 units (U) was given intranasally to supine healthy participants on repeated weekly visits. Study population Adult volunteers determined to be healthy, based on medical history, physical examination, and routine laboratory testing, were included in this study. Participants of child‐bearing potential had a negative urine pregnancy test. We excluded volunteers with a body mass index <18 or >35 kg/m2, known allergy to insulin, pre‐existing diabetes, or current

Read the complete text